KUALA LUMPUR: IHH Healthcare Bhd today announced that it has invested an undisclosed amount into sleep disorder detection and diagnosis company Belun Technology Company Limited.
Belun's artificial intelligence-powered, medical grade at-home wearable sleep test ring and software is the first of its kind cleared by the US Food and Drug Administration (FDA).
"Our investment in Belun underscores our commitment to enhance care and services to our patients through the strategic adoption of AI and other innovative technologies. By partnering with promising ventures, we are expanding our capabilities and creating value across the healthcare continuum. As the global prevalence of sleep disorders rises alongside related health challenges, IHH as a leading healthcare provider is taking steps to make sleep health services more convenient and accessible, extending holistic care beyond our hospital walls," IHH Healthcare group chief executive officer Dr Prem Nair said in the statement.
Besides offering the Belun platform at its clinics and hospitals, IHH Healthcare is exploring further collaboration with Belun to address other health conditions linked to sleep disorders.
Sleep problems constitute a global epidemic that threatens the health and quality of life for up to 45 per cent of the world's population; most sleep disorders are preventable or treatable, yet less
than one-third of sufferers seek professional help.
Belun Technology, which specialises in AI-powered sleep diagnostic and screening solutions, offers holistic management of sleep apnea and other sleep disorders, from initial diagnosis to long-term monitoring.
Its AI-powered, medical grade wearable ring and software has also been clinically validated in accredited sleep labs, helping physicians and sleep specialists understand the patient's sleep stages better so they can formulate a personalised treatment plan.